(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 84.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.35%.
Opus Genetics's revenue in 2026 is $14,196,000.On average, 15 Wall Street analysts forecast IRD's revenue for 2026 to be $1,171,967,069, with the lowest IRD revenue forecast at $557,808,513, and the highest IRD revenue forecast at $1,964,780,878. On average, 13 Wall Street analysts forecast IRD's revenue for 2027 to be $1,370,686,352, with the lowest IRD revenue forecast at $557,808,513, and the highest IRD revenue forecast at $2,745,285,901.
In 2028, IRD is forecast to generate $7,263,606,004 in revenue, with the lowest revenue forecast at $766,986,705 and the highest revenue forecast at $48,895,758,195.